(Total Views: 770)
Posted On: 11/19/2021 6:33:00 PM
Post# of 148878
An article was posted today on DelveInsight about HIV drugs. There is a brief writeup about Leronlimab (among other drugs). They do market research analysis.
Here are some excerpts:
DelveInsight estimates that the HIV-1 market size in seven major markets was USD 22,663 million in 2020, which is further expected to increase by 2030 at a Compound Annual Growth Rate of 4.60%.
Although life-saving yes, but currently the HIV drugs in the market can cause certain unwanted side effects like skin rashes, weight gain, nausea, fatigue, and insomnia. Some problems might not even occur after several months of HIV medicine intake that include high cholesterol which eventually leads to an increased risk of heart disease, and a person already weak in immunity can not take risk of such a serious disorder. Some specific HIV medications may lead to renal toxicity, including proximal tubulopathy and acute or chronic renal insufficiency, especially when combined with pharmacologic boosters. Osteomalacia has also been reported as a consequence of proximal tubulopathy.
Vyrologix/Leronlimab (PRO 140)
CytoDyn’s lead product, Vyrologix/Leronlimab, is a monoclonal antibody that belongs to a new HIV AIDS therapeutics class that protects healthy cells from viral infection. HAART (highly active antiretroviral therapy), the current standard of care for HIV treatment, waits until the Human Immunodeficiency Virus enters the cell and begins replicating before it attacks the virus. Leronlimab is a self-injectable, subcutaneous injection for HIV treatment. Advantages over the current standard of care, HAART, include no serious side effects and no serious adverse events (SAE’s) related to Leronlimab with exposure to over 800 patients, enhanced compliance, and longer half-life. Seventy-six percent of patients have resistance to at least one drug with HAART. The FDA has granted Fast Track designation and recently granted Rolling Review for Leronlimab. The company has initiated the resubmission of its Biologics License Application for HIV under rolling review consistent with guidance from the US FDA. The emerging drug is expected to launch in 2022.
https://www.delveinsight.com/blog/emerging-th...Rh_DOIXaLY
Here are some excerpts:
DelveInsight estimates that the HIV-1 market size in seven major markets was USD 22,663 million in 2020, which is further expected to increase by 2030 at a Compound Annual Growth Rate of 4.60%.
Although life-saving yes, but currently the HIV drugs in the market can cause certain unwanted side effects like skin rashes, weight gain, nausea, fatigue, and insomnia. Some problems might not even occur after several months of HIV medicine intake that include high cholesterol which eventually leads to an increased risk of heart disease, and a person already weak in immunity can not take risk of such a serious disorder. Some specific HIV medications may lead to renal toxicity, including proximal tubulopathy and acute or chronic renal insufficiency, especially when combined with pharmacologic boosters. Osteomalacia has also been reported as a consequence of proximal tubulopathy.
Vyrologix/Leronlimab (PRO 140)
CytoDyn’s lead product, Vyrologix/Leronlimab, is a monoclonal antibody that belongs to a new HIV AIDS therapeutics class that protects healthy cells from viral infection. HAART (highly active antiretroviral therapy), the current standard of care for HIV treatment, waits until the Human Immunodeficiency Virus enters the cell and begins replicating before it attacks the virus. Leronlimab is a self-injectable, subcutaneous injection for HIV treatment. Advantages over the current standard of care, HAART, include no serious side effects and no serious adverse events (SAE’s) related to Leronlimab with exposure to over 800 patients, enhanced compliance, and longer half-life. Seventy-six percent of patients have resistance to at least one drug with HAART. The FDA has granted Fast Track designation and recently granted Rolling Review for Leronlimab. The company has initiated the resubmission of its Biologics License Application for HIV under rolling review consistent with guidance from the US FDA. The emerging drug is expected to launch in 2022.
https://www.delveinsight.com/blog/emerging-th...Rh_DOIXaLY
(8)
(0)Scroll down for more posts ▼
